The program includes the Catalyst Site Network, a group of high-performing, strategic and therapeutic sites, and the Catalyst Community, an online support forum representing a broader range of sites, all focused on enhancing collaborations with clinical research sites to drive improvement and development of best practices. The program also aims to reduce variability and increase predictability of clinical trials.
INC Catalyst Sites will have the opportunity to participate in an increased volume of clinical trials, with a dedicated manager supporting the site and facilitating optimal matching to protocols. Participation in the Catalyst Site network is by invitation only and will initially focus on oncology and vaccine sites in the U.S. and Asia/Pacific region.The Catalyst Community is open to all sites and is planned for launch in 2Q16.
“Sites play an essential role in bringing new therapies to market for patients,” said Clare Grace, Ph.D., vice president, Site and Patient Access. “By involving them early on and making them a partner in the clinical development process, studies start more quickly and run more predictably, enabling INC to better deliver on the needs of our customers and ultimately accelerate the delivery of new therapies to patients. The launch of our Catalyst program underscores INC’s continued efforts and commitment to strengthening our connections with this critical stakeholder group to drive innovation in clinical research.”